{"ticker": {"uuid": "e2b47bef-4e47-4d5a-b1b8-a7d99654827c", "symbol": "CAPR", "name": "Capricor Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why", "summary": "Capricor Therapeutics (NASDAQ:CAPR) shares recently fell below their 200-day moving average, trading as low as $18.98, significantly under the $27.65 average. Despite this, analyst sentiment remains largely positive with a consensus \"Moderate Buy\" rating and an average price targ", "url": "https://www.marketbeat.com/instant-alerts/capricor-therapeutics-nasdaqcapr-share-price-crosses-below-two-hundred-day-moving-average-heres-why-2026-07-22/", "source_name": "MarketBeat", "published_at": "2026-07-22T07:39:28", "published_display": "22 Jul 2026 07:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricor\u2019s DMD Therapy Faces FDA Panel Review Next Week, Retail Sees 'Excellent Opportunity'", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPS2lHTlM0M2RjRHhjUEtyTF9LU05vNFhNWGRPTWtrMmVrX01jMXk5azZoX1ZWNkVOT3BiODd5dkpKLVFMbjluWXg4NFRvdmlCYW8wNUVSSlBMSnVhbW9heWNEQmRFUnVZN2tXSmcwOG53TER1TWdSZnE4TmZvWktCa2l1akY4Ri1NbXg5Ti1seFA1WVZyUlpxU1dON2sxSWhKaFItOVZCVGRVRmhJOWlReTFRWlhTa1NiS0VTSGJB?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-22T03:33:00+00:00", "published_display": "22 Jul 2026 03:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA\u2019s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPLWRQVmNDeVppWjJ4YnhJZml3NDFBc1hLTW1jMzFXbTRNeW82RXVMb3A2cmJYX2NjWVhfQk9hX1NXUFlsUDRzcVlxVjhlWDZhSG1qRWVoTDZPUTQ3WWh3RTNMOHdzUUNybWVjOFhIelRvdmVhNmFva3l4NXBhQmdqVmJyaWVsY2c5S2U0MzNMeWZkTW9qTjVNdG5sYkJRcHFWYVM3QVlaZGRxZW9nSHVlRWlyVWY4N0dtZWRlQVZ4dw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-21T17:10:33+00:00", "published_display": "21 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Capricor Therapeutics\u2019 (CAPR) FDA-Linked HQ Expansion Reshape Its Risk Profile And Strategic Flexibility?", "summary": "Capricor Therapeutics has leased a new 171,000 sq ft headquarters in San Diego, contingent on FDA approval of its drug Deramiocel for Duchenne muscular dystrophy by December 31, 2026. This significant expansion directly ties the company's future facilities to a critical regulator", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/can-capricor-therapeutics-capr-fda-linked-hq-expansion-resha", "source_name": "Simply Wall Street", "published_at": "2026-07-18T18:09:50", "published_display": "18 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTFFYWEQ3bFlhd0dLRXRwMWVEVmNlbktHTEo1eGZRZUdyMWpwRU5xdzJCZTNVVXRrZmNKSFNQT0syakxDQ1B4S0hqa2dqZjhZZEg0YkxTVnRWRktWRHR6YjhrbVB2TVFNbnhCWHZwOEtzY0NOaFZyRUpMTnJ2M2lPRUE1SUtwaHFPZmY2WUU4SU1mSVhlcmZNV1F3MktUSVp3RDZ5aFVSU3p5VkNCSnFjYUduUnNZekluaVhj?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-18T06:10:10+00:00", "published_display": "18 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Signs Expansion Lease Tied To Deramiocel FDA Approval", "summary": "Capricor Therapeutics has signed a major headquarters relocation and expansion lease directly linked to the potential FDA approval of its lead therapy, Deramiocel, for Duchenne muscular dystrophy. This strategic move aligns Capricor's future operational growth, including expanded", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/capricor-therapeutics-capr-signs-expansion-lease-tied-to-der", "source_name": "Simply Wall Street", "published_at": "2026-07-17T06:11:17", "published_display": "17 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Capricor Therapeutics, Inc. Stocks", "summary": "This article lists various ETFs that include Capricor Therapeutics, Inc. (4LN2) stocks in their portfolios. It provides a detailed table outlining each ETF's market value, weight, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, and 3-year ", "url": "https://www.tradingview.com/symbols/GETTEX-4LN2/etfs/", "source_name": "TradingView", "published_at": "2026-07-17T04:40:22", "published_display": "17 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cantor Fitzgerald reiterates Overweight on Capricor stock at $62", "summary": "Cantor Fitzgerald has reiterated an Overweight rating and a $62.00 price target for Capricor Therapeutics (NASDAQ:CAPR). The firm anticipates FDA approval for deramiocel, a Duchenne muscular dystrophy treatment, following its August 22 PDUFA date and plans to discuss early launch", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-on-capricor-stock-at-62-93CH-4793358", "source_name": "Investing.com", "published_at": "2026-07-15T13:40:05", "published_display": "15 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (NASDAQ: CAPR) signs 171,000 sq ft San Diego HQ lease", "summary": "Capricor Therapeutics (NASDAQ: CAPR) has signed a long-term lease for a new 171,000 sq ft headquarters in San Diego, which will include expanded manufacturing cleanrooms and R&D labs. The lease commencement is contingent on FDA approval of its drug Deramiocel for Duchenne muscula", "url": "https://www.stocktitan.net/sec-filings/CAPR/8-k-capricor-therapeutics-inc-reports-material-event-aa3271ede72f.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:49:36", "published_display": "14 Jul 2026 20:49", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Below 200 Day Moving Average - Time to Sell?", "summary": "Capricor Therapeutics (NASDAQ:CAPR) shares recently traded below their 200-day moving average, reaching $20.17 compared to the average of $28.05. Despite this, analysts maintain a \"Moderate Buy\" rating with a consensus price target of $53.67. The company also reported a wider-tha", "url": "https://www.marketbeat.com/instant-alerts/capricor-therapeutics-nasdaqcapr-shares-cross-below-200-day-moving-average-time-to-sell-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T07:40:45", "published_display": "14 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Behavioral Patterns of CAPR and Institutional Flows", "summary": "This article analyzes Capricor Therapeutics Inc. (NASDAQ: CAPR), highlighting a weak near- and mid-term sentiment that contrasts with a positive long-term outlook. AI-generated trading strategies are provided for position trading, momentum breakout, and risk hedging. The analysis", "url": "https://news.stocktradersdaily.com/news_release/34/Behavioral_Patterns_of_CAPR_and_Institutional_Flows_071326041601_1783930561.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T04:12:19", "published_display": "13 Jul 2026 04:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough", "summary": "Capricor Therapeutics (CAPR) is highlighted as a pioneer in exosome technology, particularly with its lead drug Deramiocel targeting Duchenne Muscular Dystrophy (DMD). The article emphasizes the strong clinical trial results for Deramiocel, especially concerning cardiac function ", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/y0j52kp4-the-exosome-pioneer-why-capricor-capr-is-poised-for-an-august-fda-breakthrough-3r2w", "source_name": "Simply Wall Street", "published_at": "2026-07-12T14:12:19", "published_display": "12 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Company Profile & Introduction", "summary": "This article provides a company profile and introduction to Capricor Therapeutics. It details the company's business activities, potentially including its therapeutic areas, pipeline, and strategic focus.", "url": "https://www.moomoo.com/stock/CAPR-US/company?chain_id=Name1K9-3FXPhg.1kk1880&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FCAPR-US%22%7D", "source_name": "Moomoo", "published_at": "2026-07-09T13:16:28", "published_display": "09 Jul 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Gets a Buy from Cantor Fitzgerald", "summary": "Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Capricor Therapeutics (CAPR) with a price target of $62.00. This rating aligns with a \"Strong Buy\" consensus from analysts, projecting a 136.29% upside. However, the company reported an increased GAAP net loss of", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CAPR-Q/pressreleases/3181490/capricor-therapeutics-capr-gets-a-buy-from-cantor-fitzgerald/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T01:09:44", "published_display": "09 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Is Down 5.8% After FDA Adcom Set, Russell Exit News - Has The Bull Case Changed?", "summary": "Capricor Therapeutics (CAPR) saw its stock drop 5.8% following news of an upcoming FDA advisory committee review for its Duchenne muscular dystrophy therapy, Deramiocel, and its removal from several Russell indexes. Despite positive long-term data for Deramiocel and an FDA review", "url": "https://www.sahmcapital.com/news/content/capricor-therapeutics-capr-is-down-58-after-fda-adcom-set-russell-exit-news-has-the-bull-case-changed-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-07T22:38:00", "published_display": "07 Jul 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $62", "summary": "Cantor Fitzgerald has reiterated its Buy rating for Capricor Therapeutics (CAPR.US), maintaining a target price of $62. This indicates a continued positive outlook from the firm regarding the company's stock performance and future prospects.", "url": "https://www.moomoo.com/news/post/72583542/cantor-fitzgerald-maintains-capricor-therapeutics-caprus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-07T12:40:53", "published_display": "07 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus", "summary": "Capricor Therapeutics (CAPR) has seen a significant 442% return over the past three years, but current market multiples suggest the stock is overvalued. While its price-to-book ratio is higher than the biotech sector average, it is slightly below its peer group, leading to a mixe", "url": "https://www.sahmcapital.com/news/content/capricor-therapeutics-capr-stock-looks-overvalued-as-its-442-run-draws-focus-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-05T12:11:30", "published_display": "05 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Capricor Therapeutics, Inc. \u2013 NASDAQ:CAPR", "summary": "This article provides the enterprise value to EBITDA forward for Capricor Therapeutics, Inc. (NASDAQ: CAPR) as presented on TradingView. It includes basic company information and navigational links typical of a financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-CAPR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T23:39:26", "published_display": "04 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (NASDAQ:CAPR) Is In A Strong Position To Grow Its Business", "summary": "This article analyzes Capricor Therapeutics (NASDAQ:CAPR), asserting that it is well-positioned for business growth. The analysis likely delves into the company's financials, pipeline, and market position to support this optimistic outlook.", "url": "https://www.moomoo.com/news/post/72473946/capricor-therapeutics-nasdaq-capr-is-in-a-strong-position-to", "source_name": "Moomoo", "published_at": "2026-07-04T13:10:46", "published_display": "04 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript", "summary": "This earnings call transcript summarizes Capricor Therapeutics Inc.'s Q4 2025 financial results and clinical developments. Key positive points include FDA acceptance of their BLA for Jeremiasel (targeting August 2026 action), promising HOPE 3 trial results for Duchenne muscular d", "url": "https://www.gurufocus.com/stock/LTS:0HTB/transcripts/8705053", "source_name": "GuruFocus", "published_at": "2026-07-04T12:10:46", "published_display": "04 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Capricor Therapeutics, Inc. \u2013 NASDAQ:CAPR", "summary": "This article displays the \"Enterprise value to revenue forward\" for Capricor Therapeutics, Inc. (NASDAQ: CAPR) on TradingView. It indicates that the market was closed at the time of viewing, with no trades observed. The content provides basic financial information access for the ", "url": "https://www.tradingview.com/symbols/NASDAQ-CAPR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T09:10:46", "published_display": "04 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Capricor Therapeutics, Inc. \u2013 NASDAQ:CAPR", "summary": "The article mentions the \"Price to sales forward\" metric for Capricor Therapeutics, Inc. (NASDAQ: CAPR). It appears to be a financial data point available on TradingView, within the company's financial overview. The content provided is minimal, focusing on navigation and data att", "url": "https://www.tradingview.com/symbols/NASDAQ-CAPR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T02:10:10", "published_display": "04 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal", "summary": "Capricor Therapeutics (CAPR) shares have experienced significant short-term pressure due to removal from Russell indices and upcoming FDA advisory committee discussions on its Duchenne muscular dystrophy therapy, Deramiocel. Despite this, the company's long-term returns remain st", "url": "https://www.sahmcapital.com/news/content/capricor-therapeutics-capr-could-be-58-undervalued-following-fda-focus-and-index-removal-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-03T23:40:41", "published_display": "03 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAPR - Capricor Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Capricor Therapeutics Inc (CAPR), including its stock performance, key financial metrics, and volatility. It covers data such as market capitalization, income, sales, insider and institutional ownership, and various performan", "url": "https://finviz.com/stock?t=CAPR&ta=0&p=d&ty=ocv&b=2&r=y1&ov=chain_date&e=2027-01-15", "source_name": "Finviz", "published_at": "2026-07-03T13:10:10", "published_display": "03 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Filed Against Capricor Therapeutics, Inc. (CAPR) - Recover Losses - Contact Levi & Korsinsky Before September 15, 2025", "summary": "A class action lawsuit has been filed against Capricor Therapeutics, Inc. (CAPR) by Levi & Korsinsky, LLP, seeking to recover losses for shareholders who purchased stock between October 9, 2024, and July 10, 2025. The lawsuit alleges securities fraud, claiming Capricor made misle", "url": "https://www.natlawreview.com/press-releases/class-action-lawsuit-filed-against-capricor-therapeutics-inc-capr-recover", "source_name": "The National Law Review", "published_at": "2026-07-01T10:40:17", "published_display": "01 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics, Inc. Financial Disclosures & Filings", "summary": "This page provides a comprehensive list of Capricor Therapeutics, Inc.'s financial disclosures and regulatory filings, offering insights into the company's performance and strategy. Key documents include earnings reports, corporate presentations, and updates on the progress of th", "url": "https://www.tradingview.com/symbols/LS-A2PLU4/documents/", "source_name": "TradingView", "published_at": "2026-07-01T00:41:06", "published_display": "01 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review", "summary": "Capricor Therapeutics (CAPR) shares recently hit a four-month low following news that two senior executives sold nearly $1.5 million in shares. This comes as the company prepares for a critical FDA review of its Duchenne muscular dystrophy treatment, Deramiocel, with an advisory ", "url": "https://finance.yahoo.com/markets/stocks/articles/capr-stock-hits-over-4-041509239.html", "source_name": "Market source", "published_at": "2026-06-30T12:15:00", "published_display": "30 Jun 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing update, specifically a Form 4 for Capricor Therapeutics Inc. The filing date is June 29, and the article was published on June 30, 2026. The content includes market data for various indices, commodities, and shares, indicatin", "url": "https://ng.investing.com/news/stock-market-news/form-4-capricor-therapeutics-inc-for-29-june-93CH-2579183", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T02:39:18", "published_display": "30 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor (NASDAQ: CAPR) EVP exercises options and sells 24,100 shares under 10b5-1 plan", "summary": "Capricor Therapeutics EVP and General Counsel Karen Krasney exercised stock options for 24,100 shares at $3.18 per share and subsequently sold all 24,100 shares in open-market transactions at a weighted average price of $30.38 per share. These sales were executed under a pre-arra", "url": "https://www.stocktitan.net/sec-filings/CAPR/form-4-capricor-therapeutics-inc-insider-trading-activity-c8cd574d0a60.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:39:19", "published_display": "30 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/capricor-therapeutics-gets-fda-advisory-120721783.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:07:21+00:00", "published_display": "29 Jun 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor (NASDAQ: CAPR) CFO sells 24,100 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWmVabFdRS0dJdWQ3TDF5YXhRd3ZnOVJtLW5hbTZKaW80TkFHZTc5WkxCdWVpVlNLd3cwRUhtdTI5OGJPXy05RkZtaVVzUzV3RENzNEpJUm9icU04NzJuS1ZwOE9sUEFFeTVTUnh3bWc3Q1pIdEJLeTZfb2ZMcUFFM0N1anhFUk5ZMFUta0ZfUVE2REh4ZWE4TTd5NWl1Mk1sWjJvbWlSemFsRnpUUzJhb0FkdW9oQnRWdHFV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/capricor-therapeutics-announces-fda-advisory-140200154.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T14:02:00+00:00", "published_display": "26 Jun 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/capricor-present-positive-five-hope-130500644.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T13:05:00+00:00", "published_display": "26 Jun 2026 13:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor\u2019s Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch \u2013 CAPR Stock Slides 11%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNM05URUtYNWQydnJUc1JPZUtDX1c5Qk00UTFfU0pZWjJmdG4ydWxicTZHVGg4MXlXRXM0Zm14cmt4VkZ1bFl4RmdvWVg1OGNtZ1kwaUtzV0dtVWFxMWRlT1phOWNNSDFKcmw2bmwzdkpVWXlXUmZqQUtWTExKYmNrMUZDV2JqOXhNRm5nVmpKNm9KSkM0dTZVa0gtbUNYdS12dkRQM2JLMlVuaDNTYkJDZ3FSeElUZkIz?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going On With Capricor Therapeutics Stock On Friday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPLU9VTnN5ZVpjS2NmNVpsTTJXZVNNRDBtd1NxamUzQ1BUU3JVMlBSdl9fMkcxM3ppTDNkSk9kQXJucjJkX0RBZkxzM09xNVpITWxDY3VZdGY3Y1EtS0ZmYm5EUFZOcENXa0ZQZ2tldmx0NDJ5WU56eDhzeVUydnZlbmxJRFhNSkVUQjY3VVdzOER5WGFkSnIwcjdIcXZEeE1vN0pCd2RtWTNrMElZb3cyR24yUThMVFJwWlE?oc=5", "source_name": "Benzinga", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor's Duchenne drug shows 5-year muscle and heart data at PPMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxON09POWZZTk0xR1J5aHZzTTdXMUtjVVVudjhaTl9KNW15dTYwakhIQ2FVQlhiWjhXdFhGVUpPRWdOZkR3aHkzVlpLSWNKaVRPWFMwRW4tbkRucDJFWVQ0YWVpZVNpR201dmtnUHo5YTkybmlFTDlGXzRuaG4xdnF0Wk1uOW9qcVJ2VHM2Y2ptYVYyTnVXV3JRLTl5eXVRaGhkM05FMF85bTV1dkEwelZYaDMxWTA3a0g3UEFOSw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor (NASDAQ: CAPR) EVP trades 900 shares in preplanned sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYUdLa2tSZ1NhUE0tQXJIU2lCeGF6N0dTNjI0VUIyVGxrUTUxS3JySVFWYnQteVptNV9hdGpPTFRHRE9aWkVVcHRhMFo2ZHBMbTFDUUdqWkRtb3V6MTlkYzh2dFhveWgxT1hIWUVGbkxUV1JkWjNtQkRFaVRHSjJGaW1ySF9mckc4Z3VHYjVsUmx2U193My1CUFd6ZHEyMkhfaE5EeTV3RHRJWkhIaWdTeU5McE15MldRdzA4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement \u2013 CAPR Stock Jumps 6%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPclRhVG9Lcl9qUkxKZktpZ1FCYmRXZTVHLW94Q3JWTXpMeXJpTk5sbmhQNjduZThxeFJwZWZpVmtPdGhtRU9YRF9HRVVnbVVXYkl3dWt2eDNpZzVOanRESnZWSWlDaGpsRDI2dTBZYXhmbkFZVlc3WmVGQS1OOFlFeGJseXdSM2FZOXdMeU5pTVFacDFyZnpSNmxodkxvQklEYUg1NXBQQjRwVC1WM0R5aHh3dDhBWURmZnFWeHo5TjQ5UQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNbHBudXVXd2tfd1dDSmZCQURNWXAyNWlyX3ZCUzA2RTNkN292NkY3STFWdTRfTFd0NWVuS2J2Tnc0V05GdHE1Y2hyNkI2NDJPMjN2MmZlcmhCUXl0dmxzSU50WTBzSXlPVUF3cXl6cURWZjdQY3BBclNuVGJIanBJVWxyTVZydlZBLUxYTzN4b2pnV2Z5aFcyc1hfQW52UXBFSjlnVXRyOG5xaTRNVzNRV2QyaXd0Y2dYWEpiRUV4ZHVJck5XemRhSlBn?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics to Present at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/capricor-therapeutics-present-upcoming-investor-132500162.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T13:25:00+00:00", "published_display": "08 Jun 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNSnpwRmY2a3ZyWXNXZzVfRk53dUxmWWYxYWg4R1p1VUg3WWtodk9aR0lUdm1faWd1SncxWUZuNFg1WndaVGE4UUhlekthdmFMNEdSZGVMTW9WamlhMGxfZFNqdDluZE45WERKQ0kwZUVKY0pvY1U4UkJITTlZWW9FQlBNajhsM0tDeG0tYTl2a1hNR3hETXp0T0pyS2Q2WFg3QnVubnU2dWRmZWF3Z0Zubmo2bDlkZVpJdzlIdFZB?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Capricor Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOTEJZWWJLREtZSnRGQXExOEN2NU1jSWsybjVJWUN0UFBtN1FZbHI4YTZhQTk1eU1wQzI2TGRLZ0U2cHJHTHIzV0lTTkJsMWk5VE9yRExSZThWbGE5bU5MSEFLSXFCMjdGWEV1ZDlsOW01cmV4bG01QU1QR1FlUkVCdkJlSnM3TVFoTkNkMHJrbHc4SWJ0Mmd6d2hMaGV6SGR6ZE8zUXhiaVlHZy1xLUdV?oc=5", "source_name": "TradingView", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Capricor Therapeutics stock tumbles after suing NS Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVXA3dGVPT1BmdjFOSUpOR2xWaWpPM3Nicjg0QThtd28xZTdrSVF3WHVTdjhKWjNORmh1S2h0dUJSdnFFWk1kbTJqWlBTS1NvUmljaHhxME5KSTZKblNjZnJreWRGNzE4OHB3VE1lSVlYZWphcXFVV0hiSFRDcW5yVFpBNzBOdVBkTVNOMXJ4T21qckVzbWk3M1VRdWtxTC1pUDgxclZRSnJRcjJiejFMd1F4cHFjVU1IVnRn?oc=5", "source_name": "Investing.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQX3Rsdi1Ga1JzSUo2bWZGa3FFUEN6ZTdGVi1NTjYwM215T3g2RXFJZnRnazVqTjBUNEt6R2hYWjY0ZVNVcGdTZm5LZzJHX1FoQm1JeVRuU1dndXZ3OHQ3dTMydDA5dFV1dDMwN3pPSnc3cW4xV1VGb3NTaFR3VmFLb1RMX3VkWGV1Rkl4Zy05dmxXdGk4eDcybG9tNmZBOHBkbmxVY3JR?oc=5", "source_name": "Fierce Pharma", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNdTFzelpvdzAtVXNLRktxOWxCdUx0dURSMDFBVncxbEUtMmlTeTdZWXdpZTNyLWZTUXpwTHFfaGpsRkU5Q1hmRmlBRFdSVkk5UnpVYTdyS09NUURVanQxRkoyR0paUkZwd2hNSXE1enJmR0wwdnNFUEduZTFUbDV1SW9oWlRnUGhSWkdrSXZn?oc=5", "source_name": "Market source", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPa2pUMU85UWl6RkpoMklZWExiSmFuMkFzNF9WaXFEaEFjZTlzRFEybGJ4a25tbjlIYmk5d25IUEszUTItR1ZOYUpUeGsxdU1yVFhyZklPOXZRMWpIc2dwSVJENS1hSXVha3lXWXd6a0xjMGxYM2kxY0FOOWpvb0NHdGFWS3FtMU1oblg5TVd4MXd5UG9fdUNGalROZHl6SlV2QmxRUGpwRjRRWkE5M0E?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-13T04:55:11+00:00", "published_display": "13 Mar 2026 04:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (NASDAQ: CAPR) Phase 3 HOPE-3 Meets Skeletal, Cardiac Goals in DMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPOXN6TjJvNVBBNUtLUUxkYXA4SmhjSE1MeXNXWGdMWmQ1XzVUcVVTSGY3RnVTUWpyX1pxLUJ6WE9GaEo1X2M5UHhyakVJWm5sSTFnQ0ZVYUt0Y0tTb2RuSU1JQmo0UWlNVTBnMmw4VmdCQUhoZEJrRHh6bGpRVElpN0ZNdWtvR19kdll5Y2lZYjNkN2VUQ09EaW9tbmFWdHBla19TVEo3R0xkYmVrSVZ6MFhBNXZEaEE?oc=5", "source_name": "Stock Titan", "published_at": "2025-12-03T08:00:00+00:00", "published_display": "03 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail \u2018Best Data\u2019 Ahead Of DMD Data Readout", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQZGN2aTZvRGRDdi1BcEp3NDhvMzhERmxUTVl3ZENfNTVILUY2TzZtTGpzejd5MmdBV2VVbTJrc1dTSGlVWGRpSGV5SUFHV0JvX3pneGFBN19PMC13U0Q1MDhxYXpPWnFVREN1TUd6ZEkwQzJudFdHUDNxZVU0elZlMGVFQ2FzYm9wOUxzYnM3NUQwYmQ1Rk45RHE3RmlFenQ2czk3TGFTUVl0OU1xTjFOUlIxNGZpbjR0VXo1bjdiV3pfdjFQRjVXb1dhcHlJRm9MRFFlbW1VQjA1aEowRWdBSUl0OUV3VF9ZRTFWVUhVaVFFVUY3M2I0?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Capricor Therapeutics Stock Skyrocket Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPb2JaNlk3Ty0yeXl3cmZDdHcxUlM3c0o5SS1TZExFM0VWRlNYcjE3bF93YlhIUXNDM2tPemMxaFJnazh4ZnVTVUg0VmFTSzhEd3ZwM1FxN2VFTTE3X2ZnVnhpOHhrclN0Mkp0UlF1UjJFX1BTTDFOTTg1QUJVU3h2Y1F4M0VNVG1sZEJzWmNsWFpIWWo1b3Z1OUdDT2ZMU3p4ZTdDMWlxazlZakYtSXFJRkc3RVZSZw?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-09T07:00:00+00:00", "published_display": "09 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why", "summary": "Capricor Therapeutics (NASDAQ:CAPR) shares recently fell below their 200-day moving average, trading as low as $18.98, significantly under the $27.65 average. Despite this, analyst sentiment remains largely positive with a consensus \"Moderate Buy\" rating and an average price targ", "url": "https://www.marketbeat.com/instant-alerts/capricor-therapeutics-nasdaqcapr-share-price-crosses-below-two-hundred-day-moving-average-heres-why-2026-07-22/", "source_name": "MarketBeat", "published_at": "2026-07-22T07:39:28", "published_display": "22 Jul 2026 07:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricor\u2019s DMD Therapy Faces FDA Panel Review Next Week, Retail Sees 'Excellent Opportunity'", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPS2lHTlM0M2RjRHhjUEtyTF9LU05vNFhNWGRPTWtrMmVrX01jMXk5azZoX1ZWNkVOT3BiODd5dkpKLVFMbjluWXg4NFRvdmlCYW8wNUVSSlBMSnVhbW9heWNEQmRFUnVZN2tXSmcwOG53TER1TWdSZnE4TmZvWktCa2l1akY4Ri1NbXg5Ti1seFA1WVZyUlpxU1dON2sxSWhKaFItOVZCVGRVRmhJOWlReTFRWlhTa1NiS0VTSGJB?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-22T03:33:00+00:00", "published_display": "22 Jul 2026 03:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA\u2019s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPLWRQVmNDeVppWjJ4YnhJZml3NDFBc1hLTW1jMzFXbTRNeW82RXVMb3A2cmJYX2NjWVhfQk9hX1NXUFlsUDRzcVlxVjhlWDZhSG1qRWVoTDZPUTQ3WWh3RTNMOHdzUUNybWVjOFhIelRvdmVhNmFva3l4NXBhQmdqVmJyaWVsY2c5S2U0MzNMeWZkTW9qTjVNdG5sYkJRcHFWYVM3QVlaZGRxZW9nSHVlRWlyVWY4N0dtZWRlQVZ4dw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-21T17:10:33+00:00", "published_display": "21 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Capricor Therapeutics\u2019 (CAPR) FDA-Linked HQ Expansion Reshape Its Risk Profile And Strategic Flexibility?", "summary": "Capricor Therapeutics has leased a new 171,000 sq ft headquarters in San Diego, contingent on FDA approval of its drug Deramiocel for Duchenne muscular dystrophy by December 31, 2026. This significant expansion directly ties the company's future facilities to a critical regulator", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/can-capricor-therapeutics-capr-fda-linked-hq-expansion-resha", "source_name": "Simply Wall Street", "published_at": "2026-07-18T18:09:50", "published_display": "18 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTFFYWEQ3bFlhd0dLRXRwMWVEVmNlbktHTEo1eGZRZUdyMWpwRU5xdzJCZTNVVXRrZmNKSFNQT0syakxDQ1B4S0hqa2dqZjhZZEg0YkxTVnRWRktWRHR6YjhrbVB2TVFNbnhCWHZwOEtzY0NOaFZyRUpMTnJ2M2lPRUE1SUtwaHFPZmY2WUU4SU1mSVhlcmZNV1F3MktUSVp3RDZ5aFVSU3p5VkNCSnFjYUduUnNZekluaVhj?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-18T06:10:10+00:00", "published_display": "18 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Signs Expansion Lease Tied To Deramiocel FDA Approval", "summary": "Capricor Therapeutics has signed a major headquarters relocation and expansion lease directly linked to the potential FDA approval of its lead therapy, Deramiocel, for Duchenne muscular dystrophy. This strategic move aligns Capricor's future operational growth, including expanded", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/capricor-therapeutics-capr-signs-expansion-lease-tied-to-der", "source_name": "Simply Wall Street", "published_at": "2026-07-17T06:11:17", "published_display": "17 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Capricor Therapeutics, Inc. Stocks", "summary": "This article lists various ETFs that include Capricor Therapeutics, Inc. (4LN2) stocks in their portfolios. It provides a detailed table outlining each ETF's market value, weight, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, and 3-year ", "url": "https://www.tradingview.com/symbols/GETTEX-4LN2/etfs/", "source_name": "TradingView", "published_at": "2026-07-17T04:40:22", "published_display": "17 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Capricor stock at $62", "summary": "Cantor Fitzgerald has reiterated an Overweight rating and a $62.00 price target for Capricor Therapeutics (NASDAQ:CAPR). The firm anticipates FDA approval for deramiocel, a Duchenne muscular dystrophy treatment, following its August 22 PDUFA date and plans to discuss early launch", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-on-capricor-stock-at-62-93CH-4793358", "source_name": "Investing.com", "published_at": "2026-07-15T13:40:05", "published_display": "15 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (NASDAQ: CAPR) signs 171,000 sq ft San Diego HQ lease", "summary": "Capricor Therapeutics (NASDAQ: CAPR) has signed a long-term lease for a new 171,000 sq ft headquarters in San Diego, which will include expanded manufacturing cleanrooms and R&D labs. The lease commencement is contingent on FDA approval of its drug Deramiocel for Duchenne muscula", "url": "https://www.stocktitan.net/sec-filings/CAPR/8-k-capricor-therapeutics-inc-reports-material-event-aa3271ede72f.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:49:36", "published_display": "14 Jul 2026 20:49", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Below 200 Day Moving Average - Time to Sell?", "summary": "Capricor Therapeutics (NASDAQ:CAPR) shares recently traded below their 200-day moving average, reaching $20.17 compared to the average of $28.05. Despite this, analysts maintain a \"Moderate Buy\" rating with a consensus price target of $53.67. The company also reported a wider-tha", "url": "https://www.marketbeat.com/instant-alerts/capricor-therapeutics-nasdaqcapr-shares-cross-below-200-day-moving-average-time-to-sell-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T07:40:45", "published_display": "14 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of CAPR and Institutional Flows", "summary": "This article analyzes Capricor Therapeutics Inc. (NASDAQ: CAPR), highlighting a weak near- and mid-term sentiment that contrasts with a positive long-term outlook. AI-generated trading strategies are provided for position trading, momentum breakout, and risk hedging. The analysis", "url": "https://news.stocktradersdaily.com/news_release/34/Behavioral_Patterns_of_CAPR_and_Institutional_Flows_071326041601_1783930561.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T04:12:19", "published_display": "13 Jul 2026 04:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough", "summary": "Capricor Therapeutics (CAPR) is highlighted as a pioneer in exosome technology, particularly with its lead drug Deramiocel targeting Duchenne Muscular Dystrophy (DMD). The article emphasizes the strong clinical trial results for Deramiocel, especially concerning cardiac function ", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/y0j52kp4-the-exosome-pioneer-why-capricor-capr-is-poised-for-an-august-fda-breakthrough-3r2w", "source_name": "Simply Wall Street", "published_at": "2026-07-12T14:12:19", "published_display": "12 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Company Profile & Introduction", "summary": "This article provides a company profile and introduction to Capricor Therapeutics. It details the company's business activities, potentially including its therapeutic areas, pipeline, and strategic focus.", "url": "https://www.moomoo.com/stock/CAPR-US/company?chain_id=Name1K9-3FXPhg.1kk1880&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2FCAPR-US%22%7D", "source_name": "Moomoo", "published_at": "2026-07-09T13:16:28", "published_display": "09 Jul 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Gets a Buy from Cantor Fitzgerald", "summary": "Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Capricor Therapeutics (CAPR) with a price target of $62.00. This rating aligns with a \"Strong Buy\" consensus from analysts, projecting a 136.29% upside. However, the company reported an increased GAAP net loss of", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CAPR-Q/pressreleases/3181490/capricor-therapeutics-capr-gets-a-buy-from-cantor-fitzgerald/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T01:09:44", "published_display": "09 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Is Down 5.8% After FDA Adcom Set, Russell Exit News - Has The Bull Case Changed?", "summary": "Capricor Therapeutics (CAPR) saw its stock drop 5.8% following news of an upcoming FDA advisory committee review for its Duchenne muscular dystrophy therapy, Deramiocel, and its removal from several Russell indexes. Despite positive long-term data for Deramiocel and an FDA review", "url": "https://www.sahmcapital.com/news/content/capricor-therapeutics-capr-is-down-58-after-fda-adcom-set-russell-exit-news-has-the-bull-case-changed-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-07T22:38:00", "published_display": "07 Jul 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $62", "summary": "Cantor Fitzgerald has reiterated its Buy rating for Capricor Therapeutics (CAPR.US), maintaining a target price of $62. This indicates a continued positive outlook from the firm regarding the company's stock performance and future prospects.", "url": "https://www.moomoo.com/news/post/72583542/cantor-fitzgerald-maintains-capricor-therapeutics-caprus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-07T12:40:53", "published_display": "07 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus", "summary": "Capricor Therapeutics (CAPR) has seen a significant 442% return over the past three years, but current market multiples suggest the stock is overvalued. While its price-to-book ratio is higher than the biotech sector average, it is slightly below its peer group, leading to a mixe", "url": "https://www.sahmcapital.com/news/content/capricor-therapeutics-capr-stock-looks-overvalued-as-its-442-run-draws-focus-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-05T12:11:30", "published_display": "05 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Capricor Therapeutics, Inc. \u2013 NASDAQ:CAPR", "summary": "This article provides the enterprise value to EBITDA forward for Capricor Therapeutics, Inc. (NASDAQ: CAPR) as presented on TradingView. It includes basic company information and navigational links typical of a financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-CAPR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T23:39:26", "published_display": "04 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (NASDAQ:CAPR) Is In A Strong Position To Grow Its Business", "summary": "This article analyzes Capricor Therapeutics (NASDAQ:CAPR), asserting that it is well-positioned for business growth. The analysis likely delves into the company's financials, pipeline, and market position to support this optimistic outlook.", "url": "https://www.moomoo.com/news/post/72473946/capricor-therapeutics-nasdaq-capr-is-in-a-strong-position-to", "source_name": "Moomoo", "published_at": "2026-07-04T13:10:46", "published_display": "04 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript", "summary": "This earnings call transcript summarizes Capricor Therapeutics Inc.'s Q4 2025 financial results and clinical developments. Key positive points include FDA acceptance of their BLA for Jeremiasel (targeting August 2026 action), promising HOPE 3 trial results for Duchenne muscular d", "url": "https://www.gurufocus.com/stock/LTS:0HTB/transcripts/8705053", "source_name": "GuruFocus", "published_at": "2026-07-04T12:10:46", "published_display": "04 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Capricor Therapeutics, Inc. \u2013 NASDAQ:CAPR", "summary": "This article displays the \"Enterprise value to revenue forward\" for Capricor Therapeutics, Inc. (NASDAQ: CAPR) on TradingView. It indicates that the market was closed at the time of viewing, with no trades observed. The content provides basic financial information access for the ", "url": "https://www.tradingview.com/symbols/NASDAQ-CAPR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T09:10:46", "published_display": "04 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Capricor Therapeutics, Inc. \u2013 NASDAQ:CAPR", "summary": "The article mentions the \"Price to sales forward\" metric for Capricor Therapeutics, Inc. (NASDAQ: CAPR). It appears to be a financial data point available on TradingView, within the company's financial overview. The content provided is minimal, focusing on navigation and data att", "url": "https://www.tradingview.com/symbols/NASDAQ-CAPR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T02:10:10", "published_display": "04 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal", "summary": "Capricor Therapeutics (CAPR) shares have experienced significant short-term pressure due to removal from Russell indices and upcoming FDA advisory committee discussions on its Duchenne muscular dystrophy therapy, Deramiocel. Despite this, the company's long-term returns remain st", "url": "https://www.sahmcapital.com/news/content/capricor-therapeutics-capr-could-be-58-undervalued-following-fda-focus-and-index-removal-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-03T23:40:41", "published_display": "03 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAPR - Capricor Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Capricor Therapeutics Inc (CAPR), including its stock performance, key financial metrics, and volatility. It covers data such as market capitalization, income, sales, insider and institutional ownership, and various performan", "url": "https://finviz.com/stock?t=CAPR&ta=0&p=d&ty=ocv&b=2&r=y1&ov=chain_date&e=2027-01-15", "source_name": "Finviz", "published_at": "2026-07-03T13:10:10", "published_display": "03 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Filed Against Capricor Therapeutics, Inc. (CAPR) - Recover Losses - Contact Levi & Korsinsky Before September 15, 2025", "summary": "A class action lawsuit has been filed against Capricor Therapeutics, Inc. (CAPR) by Levi & Korsinsky, LLP, seeking to recover losses for shareholders who purchased stock between October 9, 2024, and July 10, 2025. The lawsuit alleges securities fraud, claiming Capricor made misle", "url": "https://www.natlawreview.com/press-releases/class-action-lawsuit-filed-against-capricor-therapeutics-inc-capr-recover", "source_name": "The National Law Review", "published_at": "2026-07-01T10:40:17", "published_display": "01 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics, Inc. Financial Disclosures & Filings", "summary": "This page provides a comprehensive list of Capricor Therapeutics, Inc.'s financial disclosures and regulatory filings, offering insights into the company's performance and strategy. Key documents include earnings reports, corporate presentations, and updates on the progress of th", "url": "https://www.tradingview.com/symbols/LS-A2PLU4/documents/", "source_name": "TradingView", "published_at": "2026-07-01T00:41:06", "published_display": "01 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review", "summary": "Capricor Therapeutics (CAPR) shares recently hit a four-month low following news that two senior executives sold nearly $1.5 million in shares. This comes as the company prepares for a critical FDA review of its Duchenne muscular dystrophy treatment, Deramiocel, with an advisory ", "url": "https://finance.yahoo.com/markets/stocks/articles/capr-stock-hits-over-4-041509239.html", "source_name": "Market source", "published_at": "2026-06-30T12:15:00", "published_display": "30 Jun 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing update, specifically a Form 4 for Capricor Therapeutics Inc. The filing date is June 29, and the article was published on June 30, 2026. The content includes market data for various indices, commodities, and shares, indicatin", "url": "https://ng.investing.com/news/stock-market-news/form-4-capricor-therapeutics-inc-for-29-june-93CH-2579183", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T02:39:18", "published_display": "30 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor (NASDAQ: CAPR) EVP exercises options and sells 24,100 shares under 10b5-1 plan", "summary": "Capricor Therapeutics EVP and General Counsel Karen Krasney exercised stock options for 24,100 shares at $3.18 per share and subsequently sold all 24,100 shares in open-market transactions at a weighted average price of $30.38 per share. These sales were executed under a pre-arra", "url": "https://www.stocktitan.net/sec-filings/CAPR/form-4-capricor-therapeutics-inc-insider-trading-activity-c8cd574d0a60.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:39:19", "published_display": "30 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/capricor-therapeutics-gets-fda-advisory-120721783.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:07:21+00:00", "published_display": "29 Jun 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor (NASDAQ: CAPR) CFO sells 24,100 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWmVabFdRS0dJdWQ3TDF5YXhRd3ZnOVJtLW5hbTZKaW80TkFHZTc5WkxCdWVpVlNLd3cwRUhtdTI5OGJPXy05RkZtaVVzUzV3RENzNEpJUm9icU04NzJuS1ZwOE9sUEFFeTVTUnh3bWc3Q1pIdEJLeTZfb2ZMcUFFM0N1anhFUk5ZMFUta0ZfUVE2REh4ZWE4TTd5NWl1Mk1sWjJvbWlSemFsRnpUUzJhb0FkdW9oQnRWdHFV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/capricor-therapeutics-announces-fda-advisory-140200154.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T14:02:00+00:00", "published_display": "26 Jun 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/capricor-present-positive-five-hope-130500644.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T13:05:00+00:00", "published_display": "26 Jun 2026 13:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor\u2019s Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch \u2013 CAPR Stock Slides 11%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNM05URUtYNWQydnJUc1JPZUtDX1c5Qk00UTFfU0pZWjJmdG4ydWxicTZHVGg4MXlXRXM0Zm14cmt4VkZ1bFl4RmdvWVg1OGNtZ1kwaUtzV0dtVWFxMWRlT1phOWNNSDFKcmw2bmwzdkpVWXlXUmZqQUtWTExKYmNrMUZDV2JqOXhNRm5nVmpKNm9KSkM0dTZVa0gtbUNYdS12dkRQM2JLMlVuaDNTYkJDZ3FSeElUZkIz?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going On With Capricor Therapeutics Stock On Friday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPLU9VTnN5ZVpjS2NmNVpsTTJXZVNNRDBtd1NxamUzQ1BUU3JVMlBSdl9fMkcxM3ppTDNkSk9kQXJucjJkX0RBZkxzM09xNVpITWxDY3VZdGY3Y1EtS0ZmYm5EUFZOcENXa0ZQZ2tldmx0NDJ5WU56eDhzeVUydnZlbmxJRFhNSkVUQjY3VVdzOER5WGFkSnIwcjdIcXZEeE1vN0pCd2RtWTNrMElZb3cyR24yUThMVFJwWlE?oc=5", "source_name": "Benzinga", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor's Duchenne drug shows 5-year muscle and heart data at PPMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxON09POWZZTk0xR1J5aHZzTTdXMUtjVVVudjhaTl9KNW15dTYwakhIQ2FVQlhiWjhXdFhGVUpPRWdOZkR3aHkzVlpLSWNKaVRPWFMwRW4tbkRucDJFWVQ0YWVpZVNpR201dmtnUHo5YTkybmlFTDlGXzRuaG4xdnF0Wk1uOW9qcVJ2VHM2Y2ptYVYyTnVXV3JRLTl5eXVRaGhkM05FMF85bTV1dkEwelZYaDMxWTA3a0g3UEFOSw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor (NASDAQ: CAPR) EVP trades 900 shares in preplanned sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYUdLa2tSZ1NhUE0tQXJIU2lCeGF6N0dTNjI0VUIyVGxrUTUxS3JySVFWYnQteVptNV9hdGpPTFRHRE9aWkVVcHRhMFo2ZHBMbTFDUUdqWkRtb3V6MTlkYzh2dFhveWgxT1hIWUVGbkxUV1JkWjNtQkRFaVRHSjJGaW1ySF9mckc4Z3VHYjVsUmx2U193My1CUFd6ZHEyMkhfaE5EeTV3RHRJWkhIaWdTeU5McE15MldRdzA4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement \u2013 CAPR Stock Jumps 6%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPclRhVG9Lcl9qUkxKZktpZ1FCYmRXZTVHLW94Q3JWTXpMeXJpTk5sbmhQNjduZThxeFJwZWZpVmtPdGhtRU9YRF9HRVVnbVVXYkl3dWt2eDNpZzVOanRESnZWSWlDaGpsRDI2dTBZYXhmbkFZVlc3WmVGQS1OOFlFeGJseXdSM2FZOXdMeU5pTVFacDFyZnpSNmxodkxvQklEYUg1NXBQQjRwVC1WM0R5aHh3dDhBWURmZnFWeHo5TjQ5UQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNbHBudXVXd2tfd1dDSmZCQURNWXAyNWlyX3ZCUzA2RTNkN292NkY3STFWdTRfTFd0NWVuS2J2Tnc0V05GdHE1Y2hyNkI2NDJPMjN2MmZlcmhCUXl0dmxzSU50WTBzSXlPVUF3cXl6cURWZjdQY3BBclNuVGJIanBJVWxyTVZydlZBLUxYTzN4b2pnV2Z5aFcyc1hfQW52UXBFSjlnVXRyOG5xaTRNVzNRV2QyaXd0Y2dYWEpiRUV4ZHVJck5XemRhSlBn?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics to Present at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/capricor-therapeutics-present-upcoming-investor-132500162.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T13:25:00+00:00", "published_display": "08 Jun 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNSnpwRmY2a3ZyWXNXZzVfRk53dUxmWWYxYWg4R1p1VUg3WWtodk9aR0lUdm1faWd1SncxWUZuNFg1WndaVGE4UUhlekthdmFMNEdSZGVMTW9WamlhMGxfZFNqdDluZE45WERKQ0kwZUVKY0pvY1U4UkJITTlZWW9FQlBNajhsM0tDeG0tYTl2a1hNR3hETXp0T0pyS2Q2WFg3QnVubnU2dWRmZWF3Z0Zubmo2bDlkZVpJdzlIdFZB?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOTEJZWWJLREtZSnRGQXExOEN2NU1jSWsybjVJWUN0UFBtN1FZbHI4YTZhQTk1eU1wQzI2TGRLZ0U2cHJHTHIzV0lTTkJsMWk5VE9yRExSZThWbGE5bU5MSEFLSXFCMjdGWEV1ZDlsOW01cmV4bG01QU1QR1FlUkVCdkJlSnM3TVFoTkNkMHJrbHc4SWJ0Mmd6d2hMaGV6SGR6ZE8zUXhiaVlHZy1xLUdV?oc=5", "source_name": "TradingView", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics stock tumbles after suing NS Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVXA3dGVPT1BmdjFOSUpOR2xWaWpPM3Nicjg0QThtd28xZTdrSVF3WHVTdjhKWjNORmh1S2h0dUJSdnFFWk1kbTJqWlBTS1NvUmljaHhxME5KSTZKblNjZnJreWRGNzE4OHB3VE1lSVlYZWphcXFVV0hiSFRDcW5yVFpBNzBOdVBkTVNOMXJ4T21qckVzbWk3M1VRdWtxTC1pUDgxclZRSnJRcjJiejFMd1F4cHFjVU1IVnRn?oc=5", "source_name": "Investing.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQX3Rsdi1Ga1JzSUo2bWZGa3FFUEN6ZTdGVi1NTjYwM215T3g2RXFJZnRnazVqTjBUNEt6R2hYWjY0ZVNVcGdTZm5LZzJHX1FoQm1JeVRuU1dndXZ3OHQ3dTMydDA5dFV1dDMwN3pPSnc3cW4xV1VGb3NTaFR3VmFLb1RMX3VkWGV1Rkl4Zy05dmxXdGk4eDcybG9tNmZBOHBkbmxVY3JR?oc=5", "source_name": "Fierce Pharma", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNdTFzelpvdzAtVXNLRktxOWxCdUx0dURSMDFBVncxbEUtMmlTeTdZWXdpZTNyLWZTUXpwTHFfaGpsRkU5Q1hmRmlBRFdSVkk5UnpVYTdyS09NUURVanQxRkoyR0paUkZwd2hNSXE1enJmR0wwdnNFUEduZTFUbDV1SW9oWlRnUGhSWkdrSXZn?oc=5", "source_name": "Market source", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPa2pUMU85UWl6RkpoMklZWExiSmFuMkFzNF9WaXFEaEFjZTlzRFEybGJ4a25tbjlIYmk5d25IUEszUTItR1ZOYUpUeGsxdU1yVFhyZklPOXZRMWpIc2dwSVJENS1hSXVha3lXWXd6a0xjMGxYM2kxY0FOOWpvb0NHdGFWS3FtMU1oblg5TVd4MXd5UG9fdUNGalROZHl6SlV2QmxRUGpwRjRRWkE5M0E?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-13T04:55:11+00:00", "published_display": "13 Mar 2026 04:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics (NASDAQ: CAPR) Phase 3 HOPE-3 Meets Skeletal, Cardiac Goals in DMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPOXN6TjJvNVBBNUtLUUxkYXA4SmhjSE1MeXNXWGdMWmQ1XzVUcVVTSGY3RnVTUWpyX1pxLUJ6WE9GaEo1X2M5UHhyakVJWm5sSTFnQ0ZVYUt0Y0tTb2RuSU1JQmo0UWlNVTBnMmw4VmdCQUhoZEJrRHh6bGpRVElpN0ZNdWtvR19kdll5Y2lZYjNkN2VUQ09EaW9tbmFWdHBla19TVEo3R0xkYmVrSVZ6MFhBNXZEaEE?oc=5", "source_name": "Stock Titan", "published_at": "2025-12-03T08:00:00+00:00", "published_display": "03 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail \u2018Best Data\u2019 Ahead Of DMD Data Readout", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQZGN2aTZvRGRDdi1BcEp3NDhvMzhERmxUTVl3ZENfNTVILUY2TzZtTGpzejd5MmdBV2VVbTJrc1dTSGlVWGRpSGV5SUFHV0JvX3pneGFBN19PMC13U0Q1MDhxYXpPWnFVREN1TUd6ZEkwQzJudFdHUDNxZVU0elZlMGVFQ2FzYm9wOUxzYnM3NUQwYmQ1Rk45RHE3RmlFenQ2czk3TGFTUVl0OU1xTjFOUlIxNGZpbjR0VXo1bjdiV3pfdjFQRjVXb1dhcHlJRm9MRFFlbW1VQjA1aEowRWdBSUl0OUV3VF9ZRTFWVUhVaVFFVUY3M2I0?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Capricor Therapeutics Stock Skyrocket Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPb2JaNlk3Ty0yeXl3cmZDdHcxUlM3c0o5SS1TZExFM0VWRlNYcjE3bF93YlhIUXNDM2tPemMxaFJnazh4ZnVTVUg0VmFTSzhEd3ZwM1FxN2VFTTE3X2ZnVnhpOHhrclN0Mkp0UlF1UjJFX1BTTDFOTTg1QUJVU3h2Y1F4M0VNVG1sZEJzWmNsWFpIWWo1b3Z1OUdDT2ZMU3p4ZTdDMWlxazlZakYtSXFJRkc3RVZSZw?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-09T07:00:00+00:00", "published_display": "09 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 60, "sentiment_summary": {"positive": 16, "negative": 7, "neutral": 37, "score": 54, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 14.85, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.4, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 16, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 19.44, "latest_week": "2026-07-17", "one_week_move": -9.6, "four_week_move": -31.5, "twelve_week_move": -44.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.024361, "market_dynamics_buy_signal": false, "relative_strength": -10.56868, "fair_value_gap": 59.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 50.2724, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.6% over one week, -31.5% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 8}, {"label": "Stocktwits", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "simplywall.st", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "Sahm", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 15}, {"label": "Regulatory and legal", "count": 8}, {"label": "Analyst action", "count": 5}, {"label": "Guidance", "count": 3}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.6% over one week, -31.5% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why"}], "updated_at": "2026-07-23T03:34:44.397367+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}